Effects of GLP-1 receptor agonists on neurological complications of diabetes
Rev Endocr Metab Disord. 2023 May 26. doi: 10.1007/s11154-023-09807-3. Online ahead of print.ABSTRACTEmerging evidence suggests that treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) could be an interesting treatment strategy to reduce neurological complications such as stroke, cognitive impairment, and peripheral neuropathy. We performed a systematic review to examine the evidence concerning the effects of GLP-1 RAs on neurological complications of diabetes. The databases used were Pubmed, Scopus and Cochrane. We selected clinical trials which analysed the effect of GLP-1 RAs on stroke, cognitive impair...
Source: ENDOCR REV - May 25, 2023 Category: Endocrinology Authors: Natalia Garc ía-Casares Guillermo Gonz ález-González Carlos de la Cruz-Cosme Francisco J Garz ón-Maldonado Carmen de Rojas-Leal Mar ía J Ariza Manuel Narv áez Miguel Ángel Barbancho Juan Antonio Garc ía-Arnés Francisco J Tinahones Source Type: research
Effects of GLP-1 receptor agonists on neurological complications of diabetes
Rev Endocr Metab Disord. 2023 May 26. doi: 10.1007/s11154-023-09807-3. Online ahead of print.ABSTRACTEmerging evidence suggests that treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) could be an interesting treatment strategy to reduce neurological complications such as stroke, cognitive impairment, and peripheral neuropathy. We performed a systematic review to examine the evidence concerning the effects of GLP-1 RAs on neurological complications of diabetes. The databases used were Pubmed, Scopus and Cochrane. We selected clinical trials which analysed the effect of GLP-1 RAs on stroke, cognitive impair...
Source: ENDOCR REV - May 25, 2023 Category: Endocrinology Authors: Natalia Garc ía-Casares Guillermo Gonz ález-González Carlos de la Cruz-Cosme Francisco J Garz ón-Maldonado Carmen de Rojas-Leal Mar ía J Ariza Manuel Narv áez Miguel Ángel Barbancho Juan Antonio Garc ía-Arnés Francisco J Tinahones Source Type: research
Effects of GLP-1 receptor agonists on neurological complications of diabetes
Rev Endocr Metab Disord. 2023 May 26. doi: 10.1007/s11154-023-09807-3. Online ahead of print.ABSTRACTEmerging evidence suggests that treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) could be an interesting treatment strategy to reduce neurological complications such as stroke, cognitive impairment, and peripheral neuropathy. We performed a systematic review to examine the evidence concerning the effects of GLP-1 RAs on neurological complications of diabetes. The databases used were Pubmed, Scopus and Cochrane. We selected clinical trials which analysed the effect of GLP-1 RAs on stroke, cognitive impair...
Source: ENDOCR REV - May 25, 2023 Category: Endocrinology Authors: Natalia Garc ía-Casares Guillermo Gonz ález-González Carlos de la Cruz-Cosme Francisco J Garz ón-Maldonado Carmen de Rojas-Leal Mar ía J Ariza Manuel Narv áez Miguel Ángel Barbancho Juan Antonio Garc ía-Arnés Francisco J Tinahones Source Type: research
Effects of GLP-1 receptor agonists on neurological complications of diabetes
Rev Endocr Metab Disord. 2023 May 26. doi: 10.1007/s11154-023-09807-3. Online ahead of print.ABSTRACTEmerging evidence suggests that treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) could be an interesting treatment strategy to reduce neurological complications such as stroke, cognitive impairment, and peripheral neuropathy. We performed a systematic review to examine the evidence concerning the effects of GLP-1 RAs on neurological complications of diabetes. The databases used were Pubmed, Scopus and Cochrane. We selected clinical trials which analysed the effect of GLP-1 RAs on stroke, cognitive impair...
Source: ENDOCR REV - May 25, 2023 Category: Endocrinology Authors: Natalia Garc ía-Casares Guillermo Gonz ález-González Carlos de la Cruz-Cosme Francisco J Garz ón-Maldonado Carmen de Rojas-Leal Mar ía J Ariza Manuel Narv áez Miguel Ángel Barbancho Juan Antonio Garc ía-Arnés Francisco J Tinahones Source Type: research
Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus
CONCLUSION: BMI scores improved after exenatide treatment for 52 weeks in T2DM patients. Weight loss was affected by baseline body weight and blood glucose level. In addition, BMI reduction from the baseline to 52 weeks was positively correlated with baseline HbA1c, hsCRP, and SBP. Trial Registration. Chinese Clinical Trial Registry (ChiCTR-1800015658).PMID:37214201 | PMC:PMC10199797 | DOI:10.1155/2022/7128859 (Source: Atherosclerosis)
Source: Atherosclerosis - May 22, 2023 Category: Cardiology Authors: Jie Zhang Tong-Zhang Xian Yu Teng Xiuzhi Wang Ming-Xiao Wu Chen Li Weihao Wang Fuli Man Xianbo Zhang Xiaoxia Wang Li-Xin Guo Source Type: research
Exenatide improves hypogonadism and attenuates inflammation in diabetic mice by modulating gut microbiota
Int Immunopharmacol. 2023 May 19;120:110339. doi: 10.1016/j.intimp.2023.110339. Online ahead of print.ABSTRACTWith the rising incidence of diabetes and its onset at a younger age, the impact on the male reproductive system has gradually gained attention. Exenatide is a glucagon-like peptide-1 receptor agonist effective in the treatment of diabetes. However, its role in diabetes-induced reproductive complications has rarely been reported. The study aimed to investigate the mechanism by which exenatide improved diabetic hypogonadism by regulating gut microbiota (GM) mediated inflammation. C57BL/6J mice were equally divided i...
Source: International Immunopharmacology - May 21, 2023 Category: Allergy & Immunology Authors: Yuping Chen Anmei Shu Ming Jiang Jinjin Jiang Qiu Du Tianbao Chen Chris Shaw Wengang Chai TianQi Chao Xiangzhe Li Qin Wu Cuixiang Gao Source Type: research
Efficacy and safety of glucagon-like peptide-1 receptor agonist combined with sodium-glucose co-transporter-2 inhibitor in the treatment of type 2 diabetes mellitus patients with obesity: a retrospective analysis study
CONCLUSIONS: A combination of DAPA and ExQW exerts a synergistic effect in the treatment of T2DM patients with obesity. However, the potential synergistic mechanism of this combination should be studied further.PMID:37193156 | PMC:PMC10182534 (Source: American Journal of Translational Research)
Source: American Journal of Translational Research - May 16, 2023 Category: Research Authors: Jingpu Wang Yajing Chen Yan Lu Heshuai Wang Yipeng Zhao Source Type: research
